Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
Tumors or cancer of the PROSTATE.
Pathological processes involving the PROSTATE or its component tissues.
A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM.
A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.
Removal of all or part of the PROSTATE, often using a cystoscope and/or resectoscope passed through the URETHRA.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.
Neoplasms containing cyst-like formations or producing mucin or serum.
A malignant epithelial tumor with a glandular organization.
An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.
Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.
Tumors or cancer of the SKIN.
A secreted prostate-specific protein which can bind non-polar steroids, cholesterol and a group of small, proline-rich peptides. The protein is specifically found in RATS and comprises three distinct secretoglobin-related subunits referred to as prostatic steroid-binding protein C1, C2 and C3.
Tumors or cancers of the KIDNEY.
Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE).
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.
The surgical removal of one or both testicles.
An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.
Steroidal compounds in which one or more carbon atoms in the steroid ring system have been substituted with nitrogen atoms.
DNA present in neoplastic tissue.
Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
A plant genus in the family ARECACEAE, order Arecales, subclass Arecidae. The fruit or the extract (Permixon) is used for PROSTATIC HYPERPLASIA.
Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands.
Inability to empty the URINARY BLADDER with voiding (URINATION).
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A structurally-related family of small, multimeric proteins that are secreted in the mucosa of mammalian epithelial tissues. A variety of proteins are classed under this heading including some secretoglobin subtypes that appear unique to a particular mammalian species, and others whose functions differ between species.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.
An orally active synthetic progestational hormone used often in combinations as an oral contraceptive.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Tumors or cancer of the LUNG.
Carrier proteins produced in the Sertoli cells of the testis, secreted into the seminiferous tubules, and transported via the efferent ducts to the epididymis. They participate in the transport of androgens. Androgen-binding protein has the same amino acid sequence as SEX HORMONE-BINDING GLOBULIN. They differ by their sites of synthesis and post-translational oligosaccharide modifications.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer located in bone tissue or specific BONES.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Tumors or cancer of the PAROTID GLAND.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the LIVER.
Surgical removal or artificial destruction of gonads.
Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.
An abnormal concretion occurring mostly in the urinary and biliary tracts, usually composed of mineral salts. Also called stones.
Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Tumors or cancer of the ENDOCRINE GLANDS.
Neoplasms composed of more than one type of neoplastic tissue.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
A saclike, glandular diverticulum on each ductus deferens in male vertebrates. It is united with the excretory duct and serves for temporary storage of semen. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Tumors or cancer of the EYE.
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
Tumors or cancer of the URINARY BLADDER.
Tumors or cancer of the NOSE.
Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
Tumors or cancer of the SALIVARY GLANDS.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
An oxidoreductase that catalyzes the conversion of 3-oxo-delta4 steroids into their corresponding 5alpha form. It plays an important role in the conversion of TESTOSTERONE into DIHYDROTESTOSTERONE and PROGESTERONE into DIHYDROPROGESTERONE.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Enzymes that catalyze inversion of the configuration around an asymmetric carbon in a substrate having one (racemase) or more (epimerase) center(s) of asymmetry. (Dorland, 28th ed) EC 5.1.
All the organs involved in reproduction and the formation and release of URINE. It includes the kidneys, ureters, BLADDER; URETHRA, and the organs of reproduction - ovaries, UTERUS; FALLOPIAN TUBES; VAGINA; and CLITORIS in women and the testes; SEMINAL VESICLES; PROSTATE; seminal ducts; and PENIS in men.
A benign epithelial tumor with a glandular organization.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.
Tumors or cancer of the UTERUS.
Lower urinary tract symptom, such as slow urinary stream, associated with PROSTATIC HYPERPLASIA in older men.
Partial or complete blockage in any part of the URETHRA that can lead to difficulty or inability to empty the URINARY BLADDER. It is characterized by an enlarged, often damaged, bladder with frequent urges to void.
Tumors or cancer of the INTESTINES.
An anti-androgen that, in the form of its acetate (CYPROTERONE ACETATE), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
The thick, yellowish-white, viscid fluid secretion of male reproductive organs discharged upon ejaculation. In addition to reproductive organ secretions, it contains SPERMATOZOA and their nutrient plasma.
Symptoms of disorders of the lower urinary tract including frequency, NOCTURIA; urgency, incomplete voiding, and URINARY INCONTINENCE. They are often associated with OVERACTIVE BLADDER; URINARY INCOMPETENCE; and INTERSTITIAL CYSTITIS. Lower urinary tract symptoms in males were traditionally called PROSTATISM.
A tube that transports URINE from the URINARY BLADDER to the outside of the body in both the sexes. It also has a reproductive function in the male by providing a passage for SPERM.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
A general term for various neoplastic diseases of the lymphoid tissue.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Tumors or cancer of the COLON.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
The mechanical laws of fluid dynamics as they apply to urine transport.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
Tumors or cancer of the MANDIBLE.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tumors or cancer of the BILE DUCTS.
Tumors or cancer of the THYMUS GLAND.
One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.
Tumors or cancer of the SPLEEN.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Cancer or tumors of the MAXILLA or upper jaw.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Tumors or cancer of the anal gland.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A surgical specialty concerned with the study, diagnosis, and treatment of diseases of the urinary tract in both sexes, and the genital tract in the male. Common urological problems include urinary obstruction, URINARY INCONTINENCE, infections, and UROGENITAL NEOPLASMS.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Pathological processes of the URINARY TRACT in both males and females.
The measurement of an organ in volume, mass, or heaviness.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Tumors or cancer of the DUODENUM.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.

Possible suppression of host resistance by estrogen therapy for prostatic cancer.(1/17465)

 (+info)

Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. (2/17465)

Glutathione-S-Transferases (GSTs) comprise a family of isoenzymes that provide protection to mammalian cells against electrophilic metabolites of carcinogens and reactive oxygen species. Previous studies have shown that the CpG-rich promoter region of the pi-class gene GSTP1 is methylated at single restriction sites in the majority of prostate cancers. In order to understand the nature of abnormal methylation of the GSTP1 gene in prostate cancer we undertook a detailed analysis of methylation at 131 CpG sites spanning the promoter and body of the gene. Our results show that DNA methylation is not confined to specific CpG sites in the promoter region of the GSTP1 gene but is extensive throughout the CpG island in prostate cancer cells. Furthermore we found that both alleles are abnormally methylated in this region. In normal prostate tissue, the entire CpG island was unmethylated, but extensive methylation was found outside the island in the body of the gene. Loss of GSTP1 expression correlated with DNA methylation of the CpG island in both prostate cancer cell lines and cancer tissues whereas methylation outside the CpG island in normal prostate tissue appeared to have no effect on gene expression.  (+info)

Using vascular structure for CT-SPECT registration in the pelvis. (3/17465)

The authors outline a method for three-dimensional registration of pelvic CT and 111In-labeled monoclonal antibody capromab pendetide (111In MoAb 7E11.C5) images using 99mTc-labeled red blood cell SPECT data. METHODS: This method of CT-SPECT registration relies on the identification of major blood vessels in the CT and 99mTc SPECT images. The vessels are segmented from the image datasets by outlining them on transverse planar slices using a mouse-based drawing tool. Stacking the transverse outlines provides a three-dimensional representation of the vascular structures. Registration is performed by matching the surfaces of the segmented volumes. Dual isotope acquisition of 111In and 99mTc activities provides precise SPECT-SPECT registration so that registration in three dimensions of the 111In MoAb and CT images is achieved by applying the same transformation obtained from the 99mTc SPECT-CT registration. RESULTS: This method provided accurate registration of pelvic structures and significantly improved interpretation of 111In MoAb 7E11.C5 exams. Furthermore, sites of involvement by prostate cancer suggested by the 111In MoAb examination could be interpreted with the bony and soft tissue (nodal) anatomy seen on CT. CONCLUSION: This method is a general clinical tool for the registration of pelvic CT and SPECT imaging data. There are immediate applications in conformal radiation therapy treatment planning for certain prostate cancer patients.  (+info)

Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer. (4/17465)

The aim of the present study was to find out whether increasing malignancy of prostate carcinoma correlates with an overall increase of loss of heterozygosity (LOH), and whether LOH typing of microdissected tumour areas can help to distinguish between multifocal or clonal tumour development. In 47 carcinomas analysed at 25 chromosomal loci, the overall LOH rate was found to be significantly lower in grade 1 areas (2.2%) compared with grade 2 (9.4%) and grade 3 areas (8.3%, P = 0.007). A similar tendency was found for the mean fractional allele loss (FAL, 0.043 for grade 1, 0.2 for grade 2 and 0.23 for grade 3, P = 0.0004). Of 20 tumours (65%) with LOH in several microdissected areas, 13 had identical losses at 1-4 loci within two or three areas, suggesting clonal development of these areas. Markers near RB, DCC, BBC1, TP53 and at D13S325 (13q21-22) showed higher loss rates in grades 2 and 3 (between 25% and 44.4%) compared with grade 1 (0-6.6%). Tumour-suppressor genes (TSGs) near these loci might, thus, be important for tumour progression. TP53 mutations were detected in 27%, but BBC1 mutations in only 7%, of samples with LOH. Evaluation of all 25 loci in every tumour made evident that each prostate cancer has its own pattern of allelic losses.  (+info)

Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. (5/17465)

It was previously shown in the PC-295 xenograft that the number of chromogranin A (CgA)-positive neuroendocrine (NE) cells increased after androgen withdrawal. NE cells did not proliferate and differentiated from G0-phase-arrested cells. Here we further characterized NE differentiation, androgen receptor status, and apoptosis-associated Bcl-2 expression in the PC-295 model after androgen withdrawal to assess the origin of NE cells. PC-295 tumor volumes decreased by 50% in 4 days. Intraperitoneal bromodeoxyuridine (BrdU) incorporation and MIB-1 labeling decreased to 0%, and the apoptosis was maximal at day 4. Androgen receptor expression and prostate-specific antigen (PSA) serum levels decreased rapidly within 2 days. The number of NE cells increased 6-fold at day 4 and 30-fold at day 7. Five and ten percent of the CgA-positive cells were BrdU positive after continuous BrdU labeling for 2 and 4 days, respectively. However, no MIB-1 expression was observed in CgA-positive cells. NE cells expressed the regulated secretory pathway marker secretogranin III but were negative for androgen receptor and Bcl-2. Bcl-2 expression did increase in the non-NE tumor cells. In conclusion, androgen withdrawal leads to a rapid PC-295 tumor regression and a proliferation-independent induction of NE differentiation. The strictly androgen-independent NE cells that were still present after 21 days differentiated mainly from G0-phase-arrested cells.  (+info)

A fluorescent orthotopic bone metastasis model of human prostate cancer. (6/17465)

Here, we report a fluorescent spontaneous bone metastatic model of human prostate cancer developed by surgical orthotopic implantation of green fluorescent protein (GFP)-expressing prostate cancer tissue. Human prostate cancer PC-3 cells were transduced with the pLEIN expression retroviral vector containing the enhanced GFP and neomycin resistance genes. Stable GFP high-expression PC-3 clones were selected in vitro with G418, which were then combined and injected s.c. in nude mice. For metastasis studies, fragments of a single highly fluorescent s.c. growing tumor were implanted by surgical orthotopic implantation in the prostate of a series of nude mice. Subsequent micrometastases and metastases were visualized by GFP fluorescence throughout the skeleton, including the skull, rib, pelvis, femur, and tibia The central nervous system, including the brain and spinal cord, was also involved with tumor, as visualized by GFP fluorescence. Systemic organs, including the lung, plural membrane, liver, kidney, and adrenal gland, also had fluorescent metastases. The metastasis pattern in this model reflects the bone and other metastatic sites of human prostate cancer. Thus, this model should be very useful for the study and development of treatment for metastatic androgen-independent prostate cancer.  (+info)

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. (7/17465)

Prostate cancer development and progression is driven by the accumulation of genetic changes, the nature of which remains incompletely understood To facilitate high-throughput analysis of molecular events taking place in primary, recurrent, and metastat prostate cancer, we constructed a tissue microarray containing small 0.6-mm cylindrical samples acquired from 371 formalin-fixed blocks, including benign prostatic hyperplasia (n = 32) and primary tumors (n = 223), as well as both locally recurrent tumors (n = 54) and metastases (n = 62) from patients with hormone-refractory disease. Fluorescence in situ hybridization (FISH) was applied to the analysis of consecutive tissue microarray sections with probes for five different genes. High-level (> or =3X) amplifications were very rare (<2%) in primary prostate cancers However, in metastases from patients with hormone-refractory disease, amplification of the androgen receptor gene was seen in 22%, MYC in 11%, and Cyclin-D1 in 5% of the cases. In specimens from locally recurrent tumors, the corresponding percentages were 23, 4, and 8%. ERBB2 and NMYC amplifications were never detected at any stage of prostate cancer progression. In conclusion, FISH to tissue microarray sections enables high-throughput analysis of genetic alterations contributing to cancer development and progression. Our results implicate a role for amplification of androgen receptor in hormonal therapy failure and that of MYC in the metastatic progression of human prostate cancer.  (+info)

Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. (8/17465)

Whether oncogenic human papilloma viruses (HPVs) are involved in the pathogenesis of prostate cancers has been a subject of great controversy. To clarify the contradictory results of investigations, with the aim of detecting viral nucleic acids in prostate cancers, we have carried out a comparative quantitation of the HPV16-E6 sequence in 84 prostate specimens. Using single-tube quantitative competitive PCR, we characterized 47 prostate cancers and 37 control tissues of benign prostatic hyperplasia. A subgroup of the prostate tumors (10 of 47; 21%) was detected as having significantly higher copy numbers of HPV16-E6 sequences when compared to the control tissue (1 of 37; 3%), using a cutoff value of 300 copies per 12,500 diploid cells (two-sided Fisher's exact test, P = 0.02). Our results indicate that the oncogenic HPV16 might contribute to the development of a subset of prostate tumors.  (+info)

TY - JOUR. T1 - Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by α-catenin. AU - Govindarajan, Rajgopal. AU - Zhao, Sumin. AU - Song, Xiao Hong. AU - Guo, Rong Jun. AU - Wheelock, Margaret. AU - Johnson, Keith R.. AU - Mehta, Parmender P. PY - 2002/12/20. Y1 - 2002/12/20. N2 - Gap junctions, composed of connexins, provide a pathway of direct intercellular communication for the diffusion of small molecules between cells. Evidence suggests that connexins act as tumor suppressors. We showed previously that expression of connexin-43 and connexin-32 in an indolent prostate cancer cell line, LNCaP, resulted in gap junction formation and growth inhibition. To elucidate the role of connexins in the progression of prostate cancer from a hormone-dependent to -independent state, we introduced connexin-43 and connexin-32 into an invasive, androgen-independent cell line, PC-3. Expression of these proteins in PC-3 cells resulted in intracellular ...
TY - JOUR. T1 - C16 and C17-heterocycle bearing androstanes. CYP17 inhibition studies and multiple effects on prostate cancer cells. AU - Moreira, V.M.. AU - Salvador, J. A. R.. AU - Matos Beja, A.. AU - Paixão, José A.. AU - Vasaitis, T. S.. AU - Njar, V. C. O.. PY - 2011/9/24. Y1 - 2011/9/24. N2 - Heterocycles are important features of biologically active molecules. Pyrrole, pyrimidine, indole, quinoline and purine are a few classes of heterocycles which have served as platforms for developing pharmaceutical agents for various applications (1). Many important naturally occurring steroids contain one or more heterocyclic ring(s), fused or attached to ring D, formed by modifications of the side chain (2). Moreover, attachment of heterocyclic moieties at diverse positions of the steroid core has provided novel compounds with a diverse range of biological activities including inhibition of cytochrome 17α-hydroxylase-C 17,20 -lyase (CYP17), one of the enzymes involved in androgen biosynthesis in ...
CyberKnife approved to treat prostate cancer at ETMC Cancer Institute - CyberKnife approved to treat prostate cancer at ETMC Cancer Institute The East Texas Medical Center Cancer Institute is the only cancer center in the region to offer the Cyber...
Metastatic castration resistant prostate cancer (mCRPC) is usually a lethal disease and molecular markers that differentiate indolent from aggressive subtypes are needed. 58 with an elevated serum prostate-specific antigen (PSA) of 5.1 ng/mL. Despite treatment with continuous luteinizing hormone-releasing hormone agonist therapy, his PSA level increased over three years to 9,940 ng/mL ten weeks prior to death. His main tumor was removed one year after diagnosis and the composite radical retropubic prostatectomy (RRP) Gleason score was 4+4=8. DNA was isolated from sections from one RRP block, which was estimated to contain 70% noncancerous cells, 15% Gleason grade 4 prostate malignancy, 10% Gleason grade 3 prostate malignancy, and 5% Gleason grade 5 prostate malignancy based on analysis of adjacent H&E stained sections. Metastatic tumors were isolated approximately 2.5 years later, after death, as part of an integrated clinical-molecular autopsy study and were 60C98% estimated cancer purity. No ...
TY - JOUR. T1 - Development of a locally advanced orthotopic prostate tumor model in rats for assessment of combined modality therapy. AU - Tumati, Vasu. AU - Mathur, Sanjeev. AU - Song, Kwang. AU - Hsieh, Jer Tsong. AU - Zhao, Dawen. AU - Takahashi, Masaya. AU - Dobin, Timothy. AU - Gandee, Leah. AU - Solberg, Timothy D.. AU - Habib, Amyn A.. AU - Saha, Debabrata. PY - 2013/5/1. Y1 - 2013/5/1. N2 - The purpose of this study was to develop an aggressive locally advanced orthotopic prostate cancer model for assessing high-dose image-guided radiation therapy combined with biological agents. For this study, we used a modified human prostate cancer (PCa) cell line, PC3, in which we knocked down a tumor suppressor protein, DAB2IP (PC3 KD). These prostate cancer cells were implanted into the prostate of nude or Copenhagen rats using either open surgical implantation or a minimally invasive procedure under ultrasound guidance. We report that: i) these DAB2IP-deficient PCa cells form a single focus of ...
Medical professionals consider the prognosis for early stage prostate cancer very good, with a relative 5-year survival rate of 100 percent, as of 2015, states the American Cancer Society....
BACKGROUND: Ubiquitination is a highly dynamic and reversible process with a central role in cell homeostasis. Deregulation of several deubiquitinating enzymes has been linked to tumor development but their specific role in prostate cancer progression remains unexplored. METHODS: RNAi screening was used to investigate the role of the ovarian tumor proteases (OTU) family of deubiquitinating enzymes on the proliferation and invasion capacity of prostate cancer cells. RhoA activity was measured in relation with OTUB1 effects on prostate cancer cell invasion. Tumor xenograft mouse model with stable OTUB1 knockdown was used to investigate OTUB1 influence in tumor growth. RESULTS: Our RNAi screening identified OTUB1 as an important regulator of prostate cancer cell invasion through the modulation of RhoA activation. The effect of OTUB1 on RhoA activation is important for androgen-induced repression of p53 expression in prostate cancer cells. In localized prostate cancer tumors OTUB1 was found overexpressed as
BACKGROUND: Ubiquitination is a highly dynamic and reversible process with a central role in cell homeostasis. Deregulation of several deubiquitinating enzymes has been linked to tumor development but their specific role in prostate cancer progression remains unexplored. METHODS: RNAi screening was used to investigate the role of the ovarian tumor proteases (OTU) family of deubiquitinating enzymes on the proliferation and invasion capacity of prostate cancer cells. RhoA activity was measured in relation with OTUB1 effects on prostate cancer cell invasion. Tumor xenograft mouse model with stable OTUB1 knockdown was used to investigate OTUB1 influence in tumor growth. RESULTS: Our RNAi screening identified OTUB1 as an important regulator of prostate cancer cell invasion through the modulation of RhoA activation. The effect of OTUB1 on RhoA activation is important for androgen-induced repression of p53 expression in prostate cancer cells. In localized prostate cancer tumors OTUB1 was found overexpressed as
Prostate-specific antigen (PSA) is a widely used specific tumor marker for prostate cancer. We experienced a case of metastatic prostate cancer that was difficult to detect by repeat prostate biopsy despite a markedly elevated serum PSA level. A 64-year-old man was referred to our hospital with lumbar back pain and an elevated serum PSA level of 2036 ng/mL. Computed tomography, bone scintigraphy, and magnetic resonance imaging showed systemic lymph node and osteoblastic bone metastases. Digital rectal examination revealed a small, soft prostate without nodules. Ten-core transrectal prostate biopsy yielded negative results. Androgen deprivation therapy (ADT) was started because of the patients severe symptoms. Twelve-core repeat transrectal prostate biopsy performed 2 months later, and transurethral resection biopsy performed 5 months later, both yielded negative results. The patient refused further cancer screening because ADT effectively relieved his symptoms. His PSA level initially decreased to 4.8
Src family kinases (SFK) integrate signal transduction for multiple receptors, regulating cellular proliferation, invasion, and metastasis in human cancer. Although Src is rarely mutated in human prostate cancer, SFK activity is increased in the majority of human prostate cancers. To determine the molecular mechanisms governing prostate cancer bone metastasis, FVB murine prostate epithelium was transduced with oncogenic v-Src. The prostate cancer cell lines metastasized in FVB mice to brain and bone. Gene expression profiling of the tumors identified activation of a CCR5 signaling module when the prostate epithelial cell lines were grown in vivo versus tissue cultures. The whole body, bone, and brain metastatic prostate cancer burden was reduced by oral CCR5 antagonist. Clinical trials of CCR5 inhibitors may warrant consideration in patients with CCR5 activation in their tumors.. ...
Background: Few previous studies of metabolic aberrations and prostate cancer risk have taken into account the fact that men with metabolic aberrations have an increased risk of death from causes other than prostate cancer. The aim of this study was to calculate, in a real-life scenario, the risk of prostate cancer diagnosis, prostate cancer death, and death from other causes.. Methods: In the Metabolic Syndrome and Cancer Project, prospective data on body mass index, blood pressure, glucose, cholesterol, and triglycerides were collected from 285,040 men. Risks of prostate cancer diagnosis, prostate cancer death, and death from other causes were calculated by use of competing risk analysis for men with normal (bottom 84%) and high (top 16%) levels of each factor, and a composite score.. Results: During a mean follow-up period of 12 years, 5,893 men were diagnosed with prostate cancer, 1,013 died of prostate cancer, and 26,328 died of other causes. After 1996, when prostate-specific antigen ...
TY - JOUR. T1 - Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. AU - Ramos, Christian G.. AU - Carvalhal, Gustavo F.. AU - Smith, Deborah S.. AU - Mager, Douglas E.. AU - Catalona, William J.. PY - 1999/1/1. Y1 - 1999/1/1. N2 - Purpose: We compare clinicopathological features, and cancer recurrence and survival rates in men with stage T1c versus T2a or T2b prostate cancer. Materials and Methods: From 1988 through 1998, 1 surgeon (W. J. C.) performed radical retropubic prostatectomy in 1,620 men with a mean age plus or minus standard deviation of 62.3 ± 7 years. Clinical stage was T1c in 39%, T2a in 22% and T2b in 39% of patients. Patients were followed with semiannual prostate specific antigen (PSA) measurement and annual digital rectal examination. Serum total PSA greater than 0.3 ng./ml., histologically confirmed local tumor recurrence or distant metastases were considered evidence of cancer recurrence. Simple univariate ...
Purpose: We assessed the midterm oncologic outcomes of vascular targeted photodynamic therapy with padeliporfin for low risk prostate cancer treatment.
Active surveillance (AS) has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low risk prostate cancer. However, what is the impact of AS on health-related quality of life (HRQoL) in patients selected or opting for this conservative form of disease management? New research published in the Journal of Urology® found that patients on AS who were tracked for three years experienced similar HRQoL as men without prostate cancer, both clinically and psychologically.
A Rac1-Cdc42 GTPase-Specific Small Molecule Inhibitor Suppresses Growth of Primary Human Prostate Cancer Xenografts and Prolongs Survival in Mice. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
At the 2019 American Society of Clinical Oncology (ACSO) Annual Meeting, results presented by two PCF-funded investigators from pivotal phase 3 clinical trials will likely lead to approval of a new class of life-extending treatment options for men with metastatic hormone-sensitive prostate cancer (mHSPC). mHSPC refers to men whose prostate cancer has spread to areas of the body outside of the prostate itself, and who are responsive to testosterone-lowering agents. This may refer to men who have had prior surgery or radiation and recurred, or men who were initially diagnosed with disease that was already metastatic (outside the prostate). Patients who are hormone-sensitive (aka, castration-sensitive) may have previously received androgen deprivation therapy (ADT) for a certain amount of time, but their cancer has not yet developed resistance to ADT. Until 2015, the standard-of-care treatment for men with mHSPC was ADT alone. ADT is a class of treatments that block the production or activity ...
Prostate cancer survival rate without treatment - Survival rates for prostate cancer - Survival rates tell what level of individuals with a similar sort and phase of cancer are as yet alive a specific timeframe (ordinarily 5 years) after they have been analyzed.
Prostate cancer is rare in men younger than 50 years of age. The chance of developing prostate cancer increases as men get older.. Family history of prostate cancer. A man whose father, brother, or son has had prostate cancer has a higher-than-average risk of prostate cancer.. Race. Prostate cancer occurs more often in African-American men than in white men. African-American men with prostate cancer are more likely to die from the disease than white men with prostate cancer.. Hormones. The prostate needs male hormones to work the way it should. The main male sex hormone is testosterone. Testosterone helps the body develop and maintain male sex characteristics.. Testosterone is changed into dihydrotestosterone (DHT) by an enzyme in the body.. DHT is important for normal prostate growth but can also cause the prostate to get bigger and may play a part in the development of prostate cancer.. Vitamin E. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) found that vitamin E taken alone ...
The bone metastasis-derived PC3 and the lymph node metastasis-derived LNCaP prostate cancer cell lines are widely studied, having been described in thousands of publications over the last four decades. Here, we report short-read whole-genome sequencing and de novo assembly of PC3 (ATCC CRL-1435) and LNCaP (clone FGC; ATCC CRL-1740) at ~70X coverage. A known homozygous mutation in TP53 and homozygous loss of PTEN were robustly identified in the PC3 cell line, whereas the LNCaP cell line exhibited a larger number of putative inactivating somatic point and indel mutations (and in particular loss of stop codon events). This study also provides preliminary evidence that loss of one or both copies of the tumour suppressor Capicua (CIC) contributes to primary tumour relapse and metastatic progression; potentially offering a treatment target for castration-resistant prostate cancer. Our work provides a resource for genetic, genomic, and biological studies employing two commonly-used prostate cancer cell ...
View more ,Prostate cancer is the second most common cause of cancer among men in Australia and worldwide. More than 1.1 million cases of prostate cancer worldwide were recorded in 2012, accounting for around 8% of all new cancer cases and 15% of cancer cases in men. Prostate cancer also accounted for 15% of the total burden of cancer in Australian men in 2012. Even with the advanced treatments developed to manage this cancer disease, the prognosis for survival in prostate cancer patients at a metastatic stage is poor. Therefore, there is a high demand for the discovery of new target-specific anti-prostate cancer drugs. This study focuses on the discovery of natural products with potential anti-prostate cancer activity. A cytotoxicity assay on the human PC3 cells, which are androgen insensitive prostate cancer cells with a highly metastatic potential, was developed to screen a subset of the Nature Bank lead-like enhanced fraction (LLEF) library. High throughput screening of 13,720 natural ...
Background: The consistent finding of a genetic susceptibility to prostate cancer suggests that there are germline sequence variants predisposing individuals to this disease. These variants could be useful in screening and treatment. Methods: We performed an exploratory genome-wide association scan in 498 men with aggressive prostate cancer and 494 control subjects selected from a population-based case-control study in Sweden. We combined the results of this scan with those for aggressive prostate cancer from the publicly available Cancer Genetic Markers of Susceptibility (CGEMS) Study. Single-nucleotide polymorphisms (SNPs) that showed statistically significant associations with the risk of aggressive prostate cancer based on two-sided allele tests were tested for their association with aggressive prostate cancer in two independent study populations composed of individuals of European or African American descent using one-sided tests and the genetic model (dominant or additive) associated with ...
Background and Objectives In previous studies, obesity (measured according to the body mass index) has correlated inconsistently with the risk of biopsy-measured prostate cancer, and specifically high-grade prostate cancer. This meta-analysis aimed to clarify these correlations. Methods A comprehensive literature search of the MEDLINE and EMBASE databases was conducted for relevant studies published through January 2014. The pooled estimates of odds ratios (OR) and confidence intervals (CI) were computed, and the meta-analysis was performed with the STATA software according to a random effects approach. Results A total of 11 studies that included 29,464 individuals were identified. A 5-kg/m2 increase in body mass index was associated with a 15% (OR, 1.15; 95% CI, 0.98-1.34) higher risk of prostate cancer detection and a 37% (OR, 1.37; 95% CI, 1.19-1.57) higher risk of high-grade prostate cancer detection at biopsy. There were no differences among the results of studies conducted in the USA, Europe or
TY - JOUR. T1 - Growth of an androgen‐sensitive human prostate cancer cell line, LNCaP, in nude mice. AU - Lim, David J.. AU - Liu, Xiang‐Lin ‐L. AU - Sutkowski, Debra M.. AU - Braun, Eva J.. AU - Lee, Chung. AU - Kozlowski, James M.. PY - 1993. Y1 - 1993. N2 - This study was undertaken to establish an androgen‐sensitive model of human prostatic carcinoma in nude mice. The androgen‐sensitive prostatic carcinoma cell line, LNCaP, was suspended in reconstituted basement membrane (Matrigel) and injected subcutaneously into nude mice. The LNCaP cell line was chosen for the study, because the cell line is androgen‐sensitive and secretes prostate specific antigen (PSA) into culture media. Following injection of 1 × 106 LNCaP cells with 0.25 ml of Matrigel, 88. of mice exhibited palpable tumor burdens after 12 weeks of observation. In addition, significant levels of PSA were observed in the serum of LNCaP‐bearing mice. Bilateral orchiectomy of mice resulted in tumor regression and ...
Lethal progression of prostate cancer metastasis can be improved by developing animal models that recapitulate the clinical conditions. We report here that cytokeratin 13 (KRT13), an intermediate filament protein, plays a directive role in prostate cancer bone, brain, and soft tissue metastases. KRT13 expression was elevated in bone, brain, and soft tissue metastatic prostate cancer cell lines and in primary and metastatic clinical prostate, lung, and breast cancer specimens. When KRT13 expression was determined at a single cell level in primary tumor tissues of 44 prostate cancer cases, KRT13 level predicted bone metastasis and the overall survival of prostate cancer patients. Genetically enforced KRT13 expression in human prostate cancer cell lines drove metastases toward mouse bone, brain and soft tissues through a RANKL-independent mechanism, as KRT13 altered the expression of genes associated with EMT, stemness, neuroendocrine/neuromimicry, osteomimicry, development, and extracellular ...
Oncolytic virotherapy for cancer treatment utilizes viruses for selective infection and death of cancer cells without any adverse effect on normal cells. We previously reported that the human respiratory syncytial virus (RSV) is a novel oncolytic virus against androgen-independent PC-3 human prostate cancer cells. The present study extends the result to androgen-dependent prostate cancer, and explores the underlying mechanism that triggers RSV-induced oncolysis of prostate cancer cells. The oncolytic effect of RSV on androgen-sensitive LNCaP human prostate cancer cells and on androgen-independent RM1 murine prostate cancer cells was studied in vitro in culture and in vivo in a xenograft or allograft tumor model. In vitro, cell viability, infectivity and apoptosis were monitored by MTT assay, viral plaque assay and annexin V staining, respectively. In vivo studies involved virus administration to prostate tumors grown in immune compromised nude mice and in syngeneic immune competent C57BL/6J mice. Anti
Prostate Cancer Treatment India, Prostate Surgery India, Prostate India, Prostate Cancer Treatment India, Prostate Cancer Treatment Cost In India Info On Cost Prostate Cancer Treatment Mumbai Delhi Bangalore India, Prostate Cancer Treatment Hospitals Center Mumbai India, Prostate Cancer Treatment Surgeon India, Prostate Cancer Treatment Doctors Mumbai India
One can say that prostate cancer survival rates look positive. By the time men are diagnosed with prostate cancer, they are around the age of 70. Many of these men face death due to other complications of health problems over the period of 5 years that is irrelevant to prostate cancer. When survival rate of prostate cancer is calculated excluding these group of men who die of other causes, the figures look very encouraging. About 99% of men with prostate cancer that is common will hold out for 5 years and more upon being diagnosed. And for most of the men whose prostate cancer has not spreaded and remain only in one area nearby, the prognosis is far more promising. Close to all of them will live for a minimum of 5 years. For men with prostate cancer that has spreaded which make up about 30%, 1 in 3 of them will live for at least 5 years after diagnosis. However, this is mere approximate statistic.. It is quite complex to understand the prognosis of your prostate cancer because of the various ...
Neurotensin is a neuroendocrine peptide acting as a trophic factor in a variety of cells in vivo but it can also function as an autocrine growth factor in human prostate cancer cells in vitro. In addition, the high-affinity G protein-coupled NT receptor (NTS1) is overexpressed in prostate cancer cell lines. Increasing evidence argues for a direct correlation between specific alternative splice variants and cancer. We detected four splice variants of the NTS1 receptor in human prostate cancer cell lines. These isoforms include one or more exons skipping as well as an alternative 5 splice donor site and are expressed in the late-stage androgen independent prostate cancer cell lines PC3 and DU145, but not in the early-stage androgen-sensitive LNCaP or in normal prostate tissue, which only express the normal transcript ...
Intermittent administration of Taxotere® (docetaxel) appears to provide as much benefit, with fewer side effects, than continuous administration of Taxotere among patients with hormone-refractory prostate cancer. These results were recently presented at the 23rd annual meeting of the European Association of Urology.. Prostate cancer is one of the most common types of cancer diagnosed in men in the United States. One frequent approach to treatment of prostate cancer is androgen deprivation therapy (ADT), also referred to as hormone therapy. Prostate cancer is stimulated to grow from exposure to the circulating male hormone testosterone. ADT reduces the production of testosterone in the male body, reducing its growth stimulatory effects on cancer cells.. Unfortunately, prostate cancer cells can become resistant to the effects of hormone therapy, a condition referred to as hormone refractory prostate cancer (HRPC) or androgen-independent prostate cancer (AIPC). Men with AIPC are often treated with ...
Prostate cancer is the most frequently diagnosed cancer in males in developed countries. To identify common prostate cancer susceptibility alleles, we genotyped 211,155 SNPs on a custom Illumina array (iCOGS) in blood DNA from 25,074 prostate cancer cases and 24,272 controls from the international PRACTICAL Consortium. Twenty-three new prostate cancer susceptibility loci were identified at genome-wide significance (P | 5 × 10(-8)). More than 70 prostate cancer susceptibility loci, explaining ∼30% of the familial risk for this disease, have now been identified. On the basis of combined risks conferred by the new and previously known risk loci, the top 1% of the risk distribution has a 4.7-fold higher risk than the average of the population being profiled. These results will facilitate population risk stratification for clinical studies.
Read more about how low risk prostate cancer patients experience continued good health related quality of life under monitored watchful waiting approach.
The Scottish Medicines Consortium (SMC) has accepted Sanofi Genzymes Jevtana (cabazitaxel) for routine use in NHS Scotland to treat metastatic hormone-refractory prostate cancer (mHRPC).. Jevtana (cabazitaxel) is a chemotherapy option available on the NHS for advanced prostate cancer that is not responsive to hormone therapies, following initial chemotherapy (docetaxel).. The decision reduces potential disparities in care across the UK for this vulnerable group of patients.. Sanofi Genzyme UK & Ireland Oncology and Immunology franchise director Dr Jasmin Hussein said: Through ongoing collaboration our treatment can now be accessed by all doctors who treat patients with metastatic hormone-refractory prostate cancer in the country.. The approval of Jevtana by the SMC is important, as it represents a new treatment choice where limited options have existed.. Nearly one in two men in Scotland will be affected by some form of prostate disease at some stage of their lives and about one in 11 men ...
An NCI Cancer Currents blog post on results from two clinical trials that showed adding abiraterone to androgen-deprivation therapy improved survival for men with metastatic hormone-sensitive prostate cancer.
Primary androgen deprivation therapy (PADT) has played an important role in the treatment of prostate cancer. We sought to identify factors of PSA progression in our series of patients with localized and locally advanced prostate cancer treated with PADT. Six-hundred forty-nine patients with localized and locally advanced prostate cancer who received PADT from 1998 to 2005 by Nara Uro-Oncology Research Group were enrolled. Age, T classification, stage, PSA level at diagnosis, Gleason score, laterality of cancer detected by biopsy and seminal vesicle involvement (SVI) were adopted as parameters of PSA progression. Coxs proportional hazards model was used to determine the predictive factors for PSA progression. The median follow-up period and the median PSA level at diagnosis were 49 months and 15 ng/mL. The 5-year disease specific survival rate, overall survival rate and PSA progression-free survival (PFS) rate were 97.9 %, 91.9 % and 71.2 %, respectively. The univariate analysis showed that the PSA
Figure 3 Deletion of the tumor suppressor Capicua (CIC) in prostate cancer (A) Genome browser display showing a CNV0 event (red dotted line) on chromosome 19 that spans CIC, PAFAH1B3, PRR19, and TMEM145 in the PC3 prostate cancer cell line. (B) Plot of putative chromosomal loss spanning the four-gene region in LNCaP (left panel) and PC3 (right panel). The x-axis represents the genomic position and the y-axis the number of normalized counts. (C) Loss of the chromosome 19 region encompassing CIC, PAFAH1B3, PRR19, and TMEM145 in the Prostate FHCRC 2016 cBioPortal data set. Individual tumor samples are shown in columns and genes in rows. (D) CIC copy number alterations in primary and metastatic prostate cancer samples from eight clinical data sets interrogated using cBioPortal. (E) Disease-free survival in primary prostate cancer patients with loss of a single CIC gene copy (n = 13 relapse events) is significantly decreased compared to those without any CIC deletion events. The Prostate (MSKCC ...
Background. Insulin-like growth factors (IGFs) have mitogenic and anti-apoptotic effects on prostate epithelial cells. Through modulation of IGF bioactivity, IGF binding proteins (IGFBPs) also have growth regulatory effects on prostate cells. Operating through the vitamin D receptor (VDR), vitamin D shows strong inhibitory effects on prostate cancer growth in both laboratory and human studies. Recent evidence indicates that vitamin D-induced prostate cancer inhibition is accompanied by increased IGFBP expression, suggesting that the vitamin D and IGF regulatory systems may operate together to affect prostate cancer. Methods. We sought to examine whether VDR gene polymorphisms affect prostate cancer risk -either independently or with plasma IGF or IGFBP levels - in a population-based case-control study in Shanghai, China. Histologically-confirmed cases of primary prostate cancer newly diagnosed between 1993 and 1995 (N = 191) and randomly selected age-matched population controls (N = 304) ...
This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with localized prostate cancer. The goal of the study is to determine if vaccine administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients. The researchers are interested in evaluating the proportion of participants with prostate cancer progression at 2 years following administration of Proscavax or active surveillance, the effect of the vaccine on prostate-specific antigen (PSA) doubling time and the assessment of adverse events in these patients. Eligible patients in this study will include men who are 18 years and older and who have a previously untreated early stage prostate cancer regardless of the date of
TY - JOUR. T1 - Prostate cancer gene therapy and the role of radiation. AU - Kaminski, J. M.. AU - Nguyen, K.. AU - Buyyounouski, M.. AU - Pollack, A.. PY - 2002/1/1. Y1 - 2002/1/1. N2 - Even though prostate cancer is detected earlier than in the pre-PSA era, prostate cancer is the second leading cause of cancer mortality in the American male. Prostate cancer therapy is not ideal, especially for high-risk localized and metastatic cancer; therefore, investigators have sought new therapeutic modalities such as angiogenesis inhibitors, inhibitors of the cell signaling pathway, vaccines, and gene therapy. Gene therapy has emerged as potential therapy for both localized and systemic prostate cancer. Gene therapy has been shown to work supra-additively with radiation in controlling prostate cancer in vivo. With further technological advances in radiation therapy, gene therapy, and the understanding of prostate cancer biology, gene therapy will potentially have an important role in prostate cancer ...
Docetaxel-based therapy has been shown to prolong survival as first-line therapy for patients with hormone refractory prostate cancer (HRPC), and has become the standard of care. The beneficial effects of any therapy in HRPC may be diverse and include reduction in tumor bulk (when measurable), reduction in prostate-specific antigen PSA, reduction in symptoms (particularly pain), or stabilization of disease. Clear reductions in tumor bulk or PSA may provide objective evidence of a treatment effect, and stabilization of disease may be just as clinically meaningful in patients who are actively progressing prior to starting therapy. Pemetrexed has shown a broad array of activity in many diseases that until now were thought to be non-responsive to chemotherapy in the second-line setting.. This trial is designed to further assess the efficacy, safety, tolerability, and pharmacogenetics of pemetrexed as a single agent in subjects with HRPC whose disease has progressed following one prior taxane-based ...
TY - JOUR. T1 - PAC1-R null isoform expression in human prostate cancer tissue. AU - Mammi, Caterina. AU - Frajese, Giovanni V.. AU - Vespasiani, Giuseppe. AU - Mariani, Stefania. AU - Gnessi, Lucio. AU - Farini, Donatella. AU - Fabbri, Andrea. AU - Frajese, Gaetano. AU - Moretti, Costanzo. PY - 2006/4/1. Y1 - 2006/4/1. N2 - BACKGROUND. PACAP is a member of the VIP/GHRH family of neuropeptides and has important effects on prostate cell proliferation. Here we analyze the expression and localization of PACAP and its specific receptor variants (PAC1-R) in tissues collected from patients undergoing prostate biopsy and surgery for benign prostatic hyperplasia (BPH) and prostate cancer (PCa). METHODS. Reverse transcriptase (RT)-polymerase chain reaction (PCR), DNA sequencing, and immunohistochemistry. RESULTS. PACAP and PAC1-R were localized by immunohistochemistry in the prostate tissue. While in healthy and BPH tissues PAC1-R positive staining is present in all the epithelial cells lining the lumen ...
The low molecular weight thiol (-SH) content of a human prostate carcinoma cell line (LNCap), important to the cellular resistance to drugs and irradiation, was investigated using three forms of thiol assay each utilizing different chemistries. The composition of the mixture was examined by derivatization of the thiols with a three-fold excess of the Ellman reagent to give mixed aromatic disulfides. The components were isolated by chromatography on C18 reverse phase silica gel followed by DE52 anion exchange separation, and then analyzed by capillary electrophoresis against prepared standards. The glutathione adduct (GSSE) and an unknown disulfide (RSSE) were the major components isolated on DE52 together with two minor ones. However, from the absorbance at 325 nm, it was found that the GSSE isolated (1.5 ± 0.2 femtomoles/cell) could only account for 28.5 ± 4.3% of the total ASF thiols. It appeared that the bulk of the thiol material had not formed a stable mixed disulfide with Ellmans reagent, and
BACKGROUND: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. METHODS: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). RESULTS: We observed no significant association between genetic variants and prostate cancer survival. CONCLUSIONS: Common genetic variants with large impact on prostate cancer survival were not observed in this study. IMPACT: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.
Validation Study Data Published in The Journal of Urology. MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that one of the ConfirmMDxfor Prostate Cancer epigenetic genes is independently associated with risk of recurrence in patients with early prostate cancer (PCa). The results from this study, published in The Journal of Urology [The Journal of Urology (2014), doi:10.1016/j.juro.2014.04.082], suggest that epigenetic analysis could play a clinical role in identifying patients who have a slow growing cancer eligible for active surveillance from those with a higher risk of recurrence who may benefit from a more aggressive therapeutic approach.. One of the most significant challenges in diagnosing early stage PCa is proper staging and grading of the patients in order to choose the best treatment plan. Current methods such as clinical staging, PSA serum level and biopsy ...
Men with metastatic castrate-resistant prostate cancer can experience an array of treatment-related side effects. Accumulating evidence suggests exercise may alleviate some of these adversities and assist in disease management. However, empirical evidence in advanced prostate cancer patients remains limited. The purpose of this study is to determine whether men with metastatic prostate cancer, who are ineligible for high-intensity exercise, can partake in a home-based, moderate-intensity exercise program and the impact of doing so on quality of life and physical fitness parameters. Thirty men with adenocarcinoma of the prostate and progressive systemic, metastatic disease will be recruited. Clinicians will screen patients against inclusion criteria to determine eligibility. All men enrolled will be prescribed a tailored, home-based, moderate-intensity exercise intervention consisting of aerobic and strengthening components for 12 weeks. Patients will receive supplementary education materials and weekly
BACKGROUND:Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for the last two decades leading to a licensure of the first therapeutic cancer vaccine, Sipuleucel-T, in 2010. However, neither Sipuleucel-T nor other experimental PCa vaccines that emerged later induce strong T-cell immunity. METHODS:In this first-in-man study, VANCE, we evaluated a novel vaccination platform based on two replication-deficient viruses, chimpanzee adenovirus (ChAd) and MVA (Modified Vaccinia Ankara), targeting the oncofetal self-antigen 5T4 in early stage PCa. Forty patients, either newly diagnosed with early-stage PCa and scheduled for radical prostatectomy or patients with stable disease on an active surveillance protocol, were recruited to the study to assess the vaccine safety and T-cell immunogenicity. Secondary and exploratory endpoints included immune infiltration into the prostate, prostate-specific antigen (PSA) change, and assessment of
Prostate cancer is the most frequently diagnosed cancer among men in the western world. The androgen receptor, a phosphoprotein, is suspected to be involved in all stages of the prostate cancer. Androgen receptor activity can be modulated by various kinases such as PKA, MAPK, AKT, and Src. Phosphorylation is an important post-translational modification and serves as a molecular on-off switch to regulate signaling. Disruptions of cellular phosphorylation are associated with various diseases such as cancer and kinases provide important drug targets. Here we present an analysis of the phosphoproteome in LNCaP human prostate cancer cells. The analytical strategy employed here used proteomics based methodologies with a combination of detergents and chaotropic reagents during trypsin digestion followed by titanium dioxide enrichment of phosphopeptides. Over the course of multiple analyses by mass spectrometry we identified a total of 746 phosphorylation sites in 540 phosphopeptides corresponding to 116
A new drug has improved overall survival among patients with hormone resistant prostate cancer. The endothelin A antagonist ZD4054 was investigated in a placebo-controlled trial among 300 patients whose hormone-resistant prostate cancer had metastasized to bone ...
Adenocarcinoma of the prostate is the most prevalent tumor in men, a major cause of morbidity and mortality mainly because of the hormone refractory component. Hormone refractory prostate cancer...
Volunteer with Prostate Cancer Research Institute. Find Prostate Cancer Research Institute volunteering opportunities at VolunteerMatch!
Study design A phase I/II clinical trial in patients with hormone refractory metastatic prostate cancer.. Primary objective phase I component of study:. To determine a safe and potentially efficacious phase II dose of azacitidine in combination with docetaxel and prednisone that can be used for the treatment of hormone refractory metastatic prostate cancer.. Primary objective phase II component of study:. To determine the therapeutic efficacy of combined therapy of azacitidine, docetaxel, and prednisone, in the treatment of hormone refractory metastatic prostate cancer. The primary measure of therapeutic efficacy is response, defined as prostate-specific antigen (PSA) response, complete response (CR), or partial response (PR).. Secondary endpoints are toxicity, duration of response, progression-free survival, and overall survival. ...
Frick J, Marberger H, Swoboda HP (May 1971). "[Hormone therapy of prostatic neoplasms]". Urologe (in German). 10 (3): 117-9. ... Block M, Bonomi P, Anderson K, Wolter J, Showel J, Pessis D, Slayton R (1981). "Treatment of stage D prostatic carcinoma with ... Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 277-. ISBN 978-1-4612-5476-8. John David ... Lebech PE, Nordentoft EL (1967). "A study of endocrine function in the treatment of benign prostatic hypertrophy with megestrol ...
Armenian HK, Lilienfeld AM, Diamond EL, Bross IDJ: Epidemiologic Characteristics of Patients with Prostatic Neoplasms, American ... Armenian HK, Lilienfeld AM, Diamond EL, Bross IDJ: Relation Between Benign Prostatic Hyperplasia to Cancer of the Prostate. A ... Armenian HK: The Relationship of Benign Prostatic Hyperplasia to Cancer of the Prostate. An Epidemiological Study. Johns ...
MeSH C12.294.260.500 - penile neoplasms MeSH C12.294.260.750 - prostatic neoplasms MeSH C12.294.260.937 - testicular neoplasms ... genital neoplasms, male MeSH C12.740.800.410.600 - penile neoplasms MeSH C12.740.800.410.650 - prostatic neoplasms MeSH C12.740 ... prostatic hyperplasia MeSH C12.294.565.625 - prostatic neoplasms MeSH C12.294.565.750 - prostatitis MeSH C12.294.644.486 - ... 875 - testicular neoplasms MeSH C12.740.800.820 - urologic neoplasms MeSH C12.740.800.820.125 - bladder neoplasms MeSH C12.740. ...
Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the original on 2011-07- ... The prostatic veins form a well-marked prostatic plexus which lies partly in the fascial sheath of the prostate and partly ... The veins forming the prostatic plexus do not contain valves and it is thought that straining to urinate causes prostatic ... The prostatic venous plexus drains into the internal iliac vein which connects with the vertebral venous plexus, this is ...
... and that the prognosis of prostatic carcinoma was split between the most prevalent and the second most prevalent neoplasm ... poorly differentiated grade neoplasm, Grade 8-10 high-grade neoplasm. Gleason pattern 1 is the most well differentiated tumor ... These are typically found incidentally on surgery for benign prostatic hyperplasia (Note: not a precursor lesion for prostatic ... Neoplasms have no glandular differentiation (thus not resembling normal prostate tissue at all). It is composed of sheets ( ...
The veins forming the prostatic plexus do not contain valves and it is thought that straining to urinate causes prostatic ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... Loss of cancer suppressor genes, early in the prostatic carcinogenesis, have been localized to chromosomes 8p, 10q, 13q, and ... Because the vas deferens deposits seminal fluid into the prostatic urethra, and secretions from the prostate gland itself are ...
The veins forming the prostatic plexus do not contain valves and it is thought that straining to urinate causes prostatic ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... "Prostate Cancer and Prostatic Diseases. doi:10.1038/s41391-017-0005-x. ISSN 1476-5608.. ... Loss of cancer suppressor genes, early in the prostatic carcinogenesis, have been localized to chromosomes 8p, 10q, 13q, and ...
The veins forming the prostatic plexus do not contain valves and it is thought that straining to urinate causes prostatic ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... Benign prostatic hyperplasia may produce similar symptoms. Other late symptoms include fatigue, due to low levels of red blood ... "Prostatic Adenocarcinoma". Stanford University School of Medicine. Retrieved 2019-10-30. Rao SR, Snaith AE, Marino D, Cheng X, ...
The veins forming the prostatic plexus do not contain valves and it is thought that straining to urinate causes prostatic ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Arhivirano s originala ... "Prostatic Adenocarcinoma". Stanford University School of Medicine. Pristupljeno 30. 10. 2019.. *^ Rao SR, Snaith AE, Marino D, ... septembar 2009). "[Clinicopathological characterization of prostatic small cell carcinoma: a case report and review of the ...
Some neoplasms of the genitourinary system may present with haematospermia. Malignant causes of haematospermia include; ... Various prostate pathologies (including prostatitis, calculi (stones), cysts, benign prostatic hyperplasia, bacterial infection ...
... genital neoplasms, male MeSH C04.588.945.440.715 - penile neoplasms MeSH C04.588.945.440.770 - prostatic neoplasms MeSH C04.588 ... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ... femoral neoplasms MeSH C04.588.149.721 - skull neoplasms MeSH C04.588.149.721.450 - jaw neoplasms MeSH C04.588.149.721.450.583 ...
It was also the first alpha blocker to be used for treatment of benign prostatic hyperplasia, although it is currently seldom ... Due to its 5-HT2A receptor antagonism, phenoxybenzamine is useful in the treatment of carcinoid tumor, a neoplasm that secretes ... "A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction". British Journal of ...
Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DG (eds ... an accurate monitor of hormone treatment in prostatic cancer". Br J Urol. 45 (6): 668-77. doi:10.1111/j.1464-410x.1973.tb12238. ...
The veins forming the prostatic plexus do not contain valves and it is thought that straining to urinate causes prostatic ... Male Genitals - Prostate Neoplasms»։ Pathology study images։ University of Virginia School of Medicine։ Արխիվացված է օրիգինալից ... 78,0 78,1 «[Clinicopathological characterization of prostatic small cell carcinoma: a case report and review of the literature ... 2011-04-28-ին։ Վերցված է 2011-04-28։ «There are many connections between the prostatic venous plexus and the vertebral veins. ...
... has been studied in the treatment of benign prostatic hyperplasia (BPH) in a 24-week trial of 15 patients at a ... Approximately 96% of bicalutamide prescriptions were written for diagnosis codes that clearly indicated neoplasm. About 1,200, ... Kenny B, Ballard S, Blagg J, Fox D (1997). "Pharmacological options in the treatment of benign prostatic hyperplasia". J. Med. ... Newling DW (1990). "The response of advanced prostatic cancer to a new non-steroidal antiandrogen: results of a multicenter ...
Some pathology grading systems apply only to malignant neoplasms (cancer); others apply also to benign neoplasms. The ... "Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974". J. Urol. ... In pathology, grading is a measure of the cell appearance in tumors and other neoplasms. ...
NOS M8000/6 Neoplasm, metastatic Neoplasm, metastatic Tumor, metastatic Tumor, secondary Tumor embolus M8000/9 Neoplasm, ... grade III Prostatic intraepithelial neoplasia, grade III (C61.9) PIN III M8149/0 Canalicular adenoma M8150/0 Islet cell adenoma ... benign M8000/1 Neoplasm, uncertain whether benign or malignant Neoplasm, NOS Tumor, NOS Unclassified tumor, uncertain whether ... M8130/1 Papillary transitional cell neoplasm of low malignant potential (C67._) Papillary urothelial neoplasm of low malignant ...
High-grade prostatic intraepithelial neoplasia is equivalent to CIS of the prostate. Bronchioloalveolar carcinoma (BAC) of the ... While they are a form of neoplasm, there is disagreement over whether CIS should be classified as cancer. This controversy also ...
Even rarer neoplasms include sarcoma, squamous cell carcinoma, yolk sac tumor, neuroendocrine carcinoma, paraganglioma, ... The ejaculatory ducts pass through the prostate gland before opening separately into the verumontanum of the prostatic urethra ... or prostatic urethra. The evolution of seminal vesicles may have been influenced by sexual selection. They occur in many groups ...
"Strontium-89 chloride for pain palliation in prostatic skeletal malignancy". The British Journal of Radiology. 64 (765): 816- ... Radioactive strontium for treating incurable pain in skeletal neoplasms]. Deutsche Medizinische Wochenschrift (in German). 98 ( ...
Usman M, Moore W, Talati R, Watkins K, Bilfinger TV (June 2012). "Irreversible electroporation of lung neoplasm: a case series ... Prostate Cancer and Prostatic Diseases. 17 (4): 343-7. doi:10.1038/pcan.2014.33. PMC 4227889. PMID 25179590. Ting F, Tran M, ... Prostate Cancer and Prostatic Diseases. 19 (1): 46-52. doi:10.1038/pcan.2015.47. PMID 26458959. S2CID 6206548. Blazevski, ...
Such mutations and epigenetic alterations can give rise to cancer (see malignant neoplasms). Germ line mutations in DNA repair ... Human neoplasias, including thyroid, prostatic, cervical, colorectal, pancreatic and ovarian carcinoma, show a strong increase ...
In older adults, the most common cause of hydronephrosis is benign prostate hyperplasia (BPH), or intrapelvic neoplasms such as ... such as from prostatic hypertrophy in older male adults). Prenatal diagnosis is possible, and in fact, most cases in pediatric ... such as that caused by bladder outflow obstruction secondary to prostatic hypertrophy) is usually treated by insertion of a ...
Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 Suppl 7: 1929-1936. doi:10.1002/ ... "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli, David G. Johns (eds.). ... 548-. ISBN 978-3-642-96158-8. Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 ( ... A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic ...
... familial Prostatic malacoplakia associated with prostatic abscess Prostatitis Protein C deficiency Protein-energy malnutrition ... familial Pancreatic diseases Pancreatic islet cell neoplasm Pancreatic islet cell tumors Pancreatic lipomatosis duodenal ... et varioliformis acuta Pityriasis rubra pilaris Piussan-Lenaerts-Mathieu syndrome Placenta disorder Placenta neoplasm Placental ... retardation-hyperkeratosis Parapsoriasis Parasitophobia Parastremmatic dwarfism Parathyroid cancer Parathyroid neoplasm ...
... prostatic acid phosphatase - prostatic intraepithelial neoplasia - prostatitis - protease inhibitor - protein kinase C - ... neoplasm - nephrotomogram - nephrotoxic - nephroureterectomy - nerve block - nerve grafting - nerve-sparing radical ... benign prostatic hyperplasia - benign prostatic hypertrophy - benign tumor - benzaldehyde - benzoylphenylurea - benzydamine - ... Hürthle cell neoplasm - hydrazine sulfate - hydromorphone - hydronephrosis - hydroureter - hydroxychloroquine - hydroxyurea - ...
Ekman P, Lewenhaupt A (1991). "Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic ... Lipkin M, Deschner E, Troncale F (1970). "Cell differentiation and the development of colonic neoplasms". CA: A Cancer Journal ... Lewenhaupt A, Ekman P, Eneroth P, Nilsson B (1990). "Tumour markers as prognostic aids in prostatic carcinoma". British Journal ... Letocha H, Eklöv S, Gronowitz S, Norlén BJ, Nilsson S (1996). "Deoxythymidine kinase in the staging of prostatic adenocarcinoma ...
Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 266-. ISBN 978-1-4612-5476-8. Ablin RJ, ... Dao, Thomas L. (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli; ... Geller J, Bora R, Roberts T, Newman H, Lin A, Silva R (July 1965). "Treatment of benign prostatic hypertrophy with ... OHPC has been used to treat benign prostatic hyperplasia in men, although evidence of effectiveness is marginal and uncertain. ...
Hinkel A, Berges RR, Pannek J, Schulze H, Senge T (1996). "Cyproterone acetate in the treatment of advanced prostatic cancer: ... ISBN 978-0-323-32195-2. Meningeal Neoplasms-Advances in Research and Treatment: 2012 Edition: ScholarlyBrief. ScholarlyEditions ... Roila F, Crinò L, Carloni G, Natalini G (September 1993). "Cyproterone acetate: hepatotoxicity and prostatic cancer treatment ... Prostate Cancer Prostatic Dis. 8 (2): 140-51. doi:10.1038/sj.pcan.4500800. PMID 15852051. Green HJ, Pakenham KI, Headley BC, ...
It is a malignant neoplasm and is one of the most treatable and curable cancers, with a survival rate above 95% if discovered ... High-grade prostatic intraepithelial neoplasia *HGPIN. *Small-cell carcinoma. *Transitional cell carcinoma ...
"Neoplasms and cancer" has been chosen to reflect the fact that not all tumours are benign. The word "cancer" has been included ... benign prostatic hypertrophy. *erectile dysfunction and premature ejaculation. *sexual dysfunction *infection *STDs ...
en:Benign prostatic hyperplasia (41) → 전립선비대증 *en:Benign tumor (32) → 양성 종양 ... en:Neoplasm (40) → 신생물 *en:Nephrotic syndrome (38) → 신증후군 *en:Nervous system disease (4) ...
benign prostatic hypertrophy. *erectile dysfunction and premature ejaculation. *sexual dysfunction *infection *STDs ...
It has been theorized that androstanolone may have less risk of benign prostatic hyperplasia and prostate cancer than ... "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DJ (eds.). Antineoplastic ... and in Australia for the treatment of benign prostatic hyperplasia (BPH).[54][55][13] It reached phase II clinical trials for ...
Testicular cancer and other neoplasms - To improve the chances of catching possible cases of testicular cancer or other health ...
benign prostatic hypertrophy. *erectile dysfunction and premature ejaculation. *sexual dysfunction *infection *STDs ...
"Neoplasms and cancer" has been chosen to reflect the fact that not all tumours are benign. The word "cancer" has been included ... 攝護腺肥大(英语:Template:Drugs used in benign prostatic hypertrophy) ...
... is a neoplasm of the testis (i.e. a tumour of the testis), and classified as a germ cell tumour. ... High-grade prostatic intraepithelial neoplasia *HGPIN. *Small-cell carcinoma. *Transitional cell carcinoma ...
Benign prostatic hyperplasia, or BPH, is a noncancerous condition that commonly affects men over the age of 50. The prostate ... such as osteoporosis or underlying neoplasm. Analogous to vertebroplasty, the purpose of sacroplasty is to provide ... "Prostate Enlargement (Benign Prostatic Hyperplasia) , NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Pfizer is currently recruiting for the NCT00235794 Prostatic Neoplasms Cancer trial. Review trial description, criteria and ...
Click on a [studies] link to search within your current results for studies in that region. Use the back button to return to this list and try another region ...
The aim of this study was to investigate a single-institution experience with radical perineal prostatectomy (RPP), radical retropubic prostatectomy (RRP) and minimally invasive radical prostatectomy (MIRP) with respect to onco-surgical outcomes in patients with intermediate-risk (IR; PSA 10-20 ng/mL, biopsy Gleason score bGS 7 or cT2b-2c) and high-risk (HR; PSA ,20 ng/mL, bGS ≥8, or ≥cT3) prostate cancer (PCa).. ...
Controls for disease:Prostatic Neoplasms , Subjects with disease:Prostatic Neoplasms United States. Details Prostatic Neoplasms ... Breast Neoplasms , Leukemia , Lymphoma, Non-Hodgkin , Neoplasms , Ovarian Neoplasms , Prostatic Neoplasms , Thyroid Neoplasms ... Colonic Neoplasms , Hematologic Neoplasms , Lung Neoplasms , Lymphoma, Non-Hodgkin , Neoplasms , Prostatic Neoplasms ... Colonic Neoplasms , Lung Neoplasms , Neoplasms , Prostatic Neoplasms 29.. Wagner SE, et al. (2009). Increased prostate cancer ...
Pete was diagnosed with a Gleason Score 10 prostate cancer. Six years later, his doctor considered him a walking miracle.
Prostatic Neoplasms, Castration-Resistant Withdrawn Phase Trials for Enzalutamide (DB08899). Back to Prostatic Neoplasms, ... DBCOND0001230 (Prostatic Neoplasms, Castration-Resistant). Withdrawn. Not Available. clinicaltrials.gov Identifier. Title. ...
Prednisone Active Not Recruiting Phase 1 Trials for Prostatic Neoplasms Treatment. Back to Prednisone ...
Malignant neoplasm of prostate , Prostate Disorders , ProSpace Balloon System Pivotal Study BP-007 ... Clinical trial for Prostatic disorder , Early , Recurrent , Prostate Cancer , ...
Prostatic neoplasms. Delayed Hem-o-Lok Clip Erosion Following Salvage Radical Prostatectomy January 20, 2015 ...
"Prostatic Neoplasms" by people in this website by year, and whether "Prostatic Neoplasms" was a major or minor topic of these ... "Prostatic Neoplasms" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms". ...
... On-line free medical diagnosis assistant. Ranked list of possible diseases from ... Ranked list of diseases related to "prostatic neoplasms, castration-resistant"Drugs, active principles and "prostatic neoplasms ... Prostatic neoplasms, castration-resistant. Tumors or cancer of the prostate which can grow in the presence of low or residual ...
PURPOSE: Acupuncture has been suggested as therapy for hot flashes in women with breast cancer and men with prostate cancer. In this systematic review, we sought to evaluate the long-term effects on vasomotor symptoms after the end of a defined treatment period of acupuncture in women with breast cancer and men with prostate cancer. METHODS: A literature search revealed 222 articles within the field. With defined exclusion criteria, we identified 17 studies. We also used the Jadad quality score and identified seven studies with a score of at least 3 ...
Prostatic‐specific antigen: An immunohistologic marker for prostatic neoplasms. Mehrdad Nadji, Seyed Z. Tabei, Albert Castro, T ... Prostatic‐specific antigen : An immunohistologic marker for prostatic neoplasms. / Nadji, Mehrdad; Tabei, Seyed Z.; Castro, ... title = "Prostatic‐specific antigen: An immunohistologic marker for prostatic neoplasms",. abstract = "Antiserum to a human ... Prostatic‐specific antigen : An immunohistologic marker for prostatic neoplasms. In: Cancer. 1981 ; Vol. 48, No. 5. pp. 1229- ...
Prostatic. Neoplasms. /mortality ; Prostatic. Neoplasms. /pathology ; Prostatic. Neoplasms. /therapy ; Prostatic. Neoplasms. , ... Prostatic. Neoplasms. /etiology ; Prostatic. Neoplasms. /mortality ; Prostatic. Neoplasms. /pathology ; Prostatic. Neoplasms. ... Prostatic. Neoplasms. /genetics ; Prostatic. Neoplasms. /metabolism ; Prostatic. Neoplasms. , Castration-Resistant/genetics ; ... Prostatic. Neoplasms. /diagnosis ; Prostatic. Neoplasms. /pathology ; Prostatic. Neoplasms. , Castration-Resistant/diagnosis ; ...
Prostatic. Neoplasms. Prostatic. Neoplasms. --physiopathology. Prostatic. Neoplasms. --. genetics. Androgen Antagonists. Text. ... Neoplasm metastasis. Neoplasm staging. Prostatic. neoplasms. /diagnosis. Prostatic. neoplasms. /. genetics. Sítios de ligac ... Prostatic. Neoplasms. /drug therapy; Prostatic. Neoplasms. /. genetics. ; Signal Transduction; Taxoids/pharmacology; Tumor ... Neoplasms. , Hormone-Dependent -- genetics. Prostatic. Neoplasms. -- genetics. RNA Precursors -- genetics. -- metabolism. ...
Prostatic Neoplasms - at Expertscape.com. Experts in 27,000 medical and life-science topics. Fast. Easy. Free. Objective. ... Expertise in Prostatic Neoplasms:. June 2019. Expertscape World Centers in Prostatic Neoplasms. *Johns Hopkins University ... Expertscape World Experts in Prostatic Neoplasms. Top 0.1% of scholars in the field ...
Prostatic Neoplasms - complications. Prostatic Neoplasms - psychology. Sexual Partners. Sexual Behavior. Adaptation, ... Prostatic Neoplasms - psychology. Pictorial Works. Cartoons. Juvenile Literature. ISBN. 9781604431988. Language. English. ...
Prostatic Neoplasms - diet therapy. Prostatic Neoplasms - prevention & control. Prostatic Neoplasms - complications. ... Prostatic Neoplasms - diet therapy. Prostatic Neoplasms - prevention & control. Nutrition. Evidence-Based Practice. Body Weight ...
Prostatic Neoplasms. Adenocarcinoma. Genital Neoplasms, Male. Urogenital Neoplasms. Neoplasms by Site. Neoplasms. Prostatic ... Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. Prednisone. Abiraterone Acetate. Anti-Inflammatory Agents. ... Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma. The safety ... Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma. ...
Prostatic Neoplasms. Carcinoma. Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. Neoplasms. Genital Neoplasms ... Urogenital Neoplasms. Neoplasms by Site. Genital Diseases, Male. Prostatic Diseases. Cyclophosphamide. Nivolumab. Ipilimumab. ... A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma. The safety and scientific validity of this study is the ... Metastatic Prostatic Adenocarcinoma Drug: Opdivo Injectable Product Drug: Yervoy Injectable Product Drug: Cytoxan Procedure: ...
Prostatic Neoplasms / enzymology* * Prostatic Neoplasms / genetics * Prostatic Neoplasms / pathology* * Protein Kinase C / ... elicits disparate functional responses in androgen-sensitive and androgen-independent human prostatic cancer cells Biochem ... results suggest that the PKC signal transduction pathway functions differently in androgen-sensitive and insensitive prostatic ...
Anorectal symptoms following RTH for prostatic carcinoma are common and persist at least until 1 year after its completion and ... Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function Int J Radiat Oncol Biol Phys ... Conclusions: Anorectal symptoms following RTH for prostatic carcinoma are common and persist at least until 1 year after its ... with localized prostatic carcinoma treated with RTH either to a dose of 55 Gy/20 fractions/4 weeks (18 patients) or 64 Gy/32 ...
Prostatic Neoplasms. September 2, 2013. Measures by Topic. Disease/Condition , Diseases (1455) , Neoplasms (181) , Neoplasms by ...
... admin , 10 December 2016 , Healthcare News ... "That learn about shows that when mice with prostatic tumors use up an total of walnuts that could handily be devoured past a ... Researchers amplify adapted aid to forewarn chances of prostatic somebody overdiagnosis * AHF opens creative Mens Upbeat Point ... Actress frs a subsistence with unharmed walnuts to mice that had back number genetically programmed to purchase prostatic sign ...
3. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms ...
Results of search for su:{Prostatic neoplasms} and itype:MONOGRAPH Refine your search. *Availability * Limit to currently ... by (2nd : International Consultation on Benign Prostatic Hyperplasia Paris, France) 1993: , Cockett, Abraham T. K , Khoury, ... The 2nd [Second] International Consultation on Benign Prostatic Hyperplasia (BPH, Paris, June 27-30, 1993 : proceedings / ...
Rosuvastatin Active Not Recruiting Phase 1 Trials for Prostatic Neoplasms, Castration-Resistant Treatment. Back to Rosuvastatin ...
PROSTATIC NEOPLASMS. D011471. EFO:0001663. PROSTATE CARCINOMA. 2. ClinicalTrials. CARCINOMA, NON-SMALL-CELL LUNG. D002289. EFO: ... MOUTH NEOPLASMS. D009062. EFO:0003868. MOUTH NEOPLASM. 3. ClinicalTrials. SKIN NEOPLASMS. D012878. EFO:0004198. SKIN NEOPLASM. ... NEOPLASMS. D009369. EFO:0000616. NEOPLASM. 4. ATC. ClinicalTrials. ESOPHAGEAL NEOPLASMS. D004938. EFO:0002916. ESOPHAGEAL ... BRAIN NEOPLASMS. D001932. EFO:0003833. BRAIN NEOPLASM. 2. ClinicalTrials. CARCINOMA, RENAL CELL. D002292. EFO:0000681. RENAL ...
Prostatic Neoplasms. D011471. EFO:0001663. prostate carcinoma. 2. ClinicalTrials. Clinical Data. ClinicalTrials.gov ...
  • Soydal C, Araz M, Urun Y, Nak D, Ozkan E, Kucuk NO. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer. (minervamedica.it)
  • Walnut phthisis slows the enlargement of endocrine crab in mice and has favourable belongings on twofold genes related the exercise power of neoplasm increase and metastasis, UC Painter and the U.S. Unit of Agronomy Hesperian Regional Enquiry Edifice in Town, Khalifah. (bellycard.org)
  • Includes neoplasms involving the prostate thru direct spread from adjacent organ or by metastasis from a distant site. (auanet.org)
  • Antiserum to a human prostate-specific antigen was raised in a rabbit and utilized by immunoperoxidase staining to evaluate its potential value as a diagnostic histologic marker for tumors of prostatic origin. (elsevier.com)
  • That learn about shows that when mice with prostatic tumors use up an total of walnuts that could handily be devoured past a gentleman, lump evolvement is regimented," he believed. (bellycard.org)
  • Abaft 18 weeks, they establish that intense the hominoid tantamount of 2.4 ounces of walnuts per period resulted in notably slighter, slower-growing prostatic tumors compared to mice intense the selfsame sustenance with an like come of chubby, but not from walnuts. (bellycard.org)
  • Essas campanhas recomendam a utilização do toque retal acompanhado da dosagem sérica do antígeno prostático específico (PSA, da sigla em inglês correspondente a prostatic specific antigen ) para homens a partir de faixas etárias definidas. (scielosp.org)
  • Anorectal symptoms following RTH for prostatic carcinoma are common and persist at least until 1 year after its completion and are associated with objective evidence of heightened rectal sensitivity. (nih.gov)
  • Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to AMPHICRINE carcinoma. (bioportfolio.com)
  • However, some are not, and prostatic adenocarcinoma is second only to lung carcinoma as a cause for tumor-related deaths among males. (humpath.com)
  • A rising tPSA is suspicious for prostatic carcinoma, even if the tPSA is in the normal range. (humpath.com)
  • High-grade prostatic intraepithelial neoplasia (PIN) is now accepted as the most likely preinvasive stage of adenocarcinoma, almost two decades after its first formal description. (nature.com)
  • A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. (bioportfolio.com)
  • Perpendicular and forward light scatter have been employed in a multiparametric approach to distinguish the various lines of the transplantable Dunning R3327 rat prostatic adenocarcinoma. (biomedsearch.com)
  • Prostatic adenocarcinoma shows prominent nucleoli and an increased nuclear size and N/C ratio. (humpath.com)
  • Definitive features of prostatic adenocarcinoma include perineural invasion, collagenous micro nodules / mucinous fibroplasia, and glomerular forms. (humpath.com)
  • It is rare before the age of 50, but autopsy studies have found prostatic adenocarcinoma in 80% of men more than 80 years old. (humpath.com)
  • proinflammatory mediators within the prostate can lead to a state of chronic inflammation resulting in lesions of proliferative inflammatory atrophy that may transition to prostatic intraepithelial neoplasia and eventually prostate adenocarcinoma ( 3 ). (aacrjournals.org)
  • High-grade prostatic intraepithelial neoplasia (PIN) is the earliest accepted stage in carcinogenesis, possessing most of the phenotypic, biochemical, and genetic changes of cancer without invasion of the basement membrane of the acini. (nature.com)
  • Prostatic intraepithelial neoplasia was originally graded from 1 to 3, but current recommendations recognize two grades of PIN (low grade and high grade). (nature.com)
  • High-grade prostatic intraepithelial neoplasia is the most likely precursor of invasive prostate cancer. (cdc.gov)
  • Prostatic intraepithelial neoplasm (PIN) is a frequent pathological finding from prostate needle biopsy. (cdc.gov)
  • Among the topics covered in Volume 49 are neurotransmitter transporters circadian rhythms, transgenic model for studying isles development, protein phosphateses, the androgen receptor, molecular genetics of steroid 5oz-reductases and benign and malignant prostatic neoplasms. (elsevier.com)
  • Benign and Malignant Prostatic Neoplasm: Human Studies. (elsevier.com)
  • These results suggest that the PKC signal transduction pathway functions differently in androgen-sensitive and insensitive prostatic cells. (nih.gov)
  • This is the first immunohistochemical marker for prostate gland epithelium which does not represent prostatic acid phosphatase. (elsevier.com)
  • PIN is associated with progressive abnormalities of phenotype and genotype, which are similar to cancer rather than normal prostatic epithelium, indicating impairment of cell differentiation with advancing stages of prostatic carcinogenesis. (nature.com)
  • To determine whether there is a decrease in the extent of prostate cancer as measured by endorectal MRI and magnetic resonance spectroscopy imaging in patients with symptomatic benign prostatic hypertrophy and low-risk prostate cancer treated with dutasteride for 6 months. (knowcancer.com)
  • 5 Reductases Inhibitors for the Treatment of Benign Prostatic Hyperplasia. (elsevier.com)
  • A total of 136 patients including 13 untreated and 40 treated patients with prostatic cancer , 45 patients with benign prostatic hyperplasia (BPH) and 38 patients with other urological diseases were analyzed. (curehunter.com)
  • The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA). (bioportfolio.com)
  • Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. (bioportfolio.com)
  • The UroLift® system for treatment of the benign prostatic syndrome (BPS). (bioportfolio.com)
  • Minimally-invasive treatment options for patients with LUTS due to benign prostatic obstruction (BPO) become more and more important because they provide equal long-term efficacy compared with the ref. (bioportfolio.com)
  • The fPSA correlates more closely with benign prostatic conditions than the tPSA. (humpath.com)
  • Although it has not been approved for these uses, MGA has been studied and/or used off-label for a variety of indications including menopausal hormone therapy and the treatment of hot flashes, gynecological/menstrual disorders, endometriosis, endometrial hyperplasia, ovarian cancer, prostate cancer, benign prostatic hyperplasia, male breast cancer, and precocious puberty. (wikipedia.org)
  • Benign prostatic hyperplasia (BPH) is an enlarged prostate gland . (northshore.org)
  • Benign prostatic hyperplasia is also known as benign prostatic hypertrophy. (northshore.org)
  • Benign prostatic hyperplasia is probably a normal part of the aging process in men, caused by changes in hormone balance and in cell growth. (northshore.org)
  • Interactive Tool: How Bad Are Your Urinary Symptoms From Benign Prostatic Hyperplasia (BPH)? (northshore.org)
  • Benign prostatic hyperplasia (BPH) is probably a normal part of the aging process in men. (northshore.org)
  • Many men with benign prostatic hyperplasia (BPH) have no symptoms. (northshore.org)
  • Failure to attempt to link left kidney abnormalities to the prostatic neoplasm. (acvr.org)
  • Prostatic capsular incision during radical prostatectomy has important oncological implications. (bioportfolio.com)
  • Clinical studies of gamma-seminoprotein in prostatic disease. (curehunter.com)
  • All primary and metastatic prostatic malignancies reacted positively, whereas nonprostatic neoplasms did not stain with this procedure. (elsevier.com)
  • Possible etiologies include infection, inflammation and less commonly, prostatic cancer. (cdc.gov)
  • Individual calculi form when the secretory tube is blocked by inflammation, prostatic secretions, or corpor. (bioportfolio.com)
  • Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. (aacrjournals.org)
  • Hematopoietic neoplasm is the most common secondary prostatic tumor. (auanet.org)
  • The stage is determined by the size and location of the cancer, whether it has invaded the prostatic capsule or seminal vesicle, and whether it has metastasized. (humpath.com)
  • Primary prostatic calculi commonly present asymptomatically in men over the age of 50 years. (bioportfolio.com)
  • Rarely, GIST from the colorectal region may invade into prostate and even present as an intraprostatic mass mimicking a primary prostatic tumor. (auanet.org)
  • The predictor analysis of response to routine treatment in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. (nel.edu)
  • Um Y, Koh J, Ko H, Cho K, Kim J, Lee S, Pae C. The predictor analysis of response to routine treatment in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. (nel.edu)
  • Treatment with activin A to an androgen-sensitive human prostatic cancer cell line LNCaP resulted in growth and morphological change and those were accompanied by up-regulation of prostatic differentiation markers prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). (nebraska.edu)
  • Prostate Cancer and Prostatic Diseases , 20 (2), 172-178. (elsevier.com)
  • Number of children with cancer in Penza region named children under the age of 14 were registered in the Penza region in due to the presence of malignant neoplasm. (theatransformation.ru)
  • Second, because even when it comes to ascertaining the presence of a neoplasm it is not said that it should be treated and if the disease is not dangerous it is useful to promote the use of active surveillance. (newsylist.com)